Edition:
United States

Stellar Biotechnologies Inc (SBOT.OQ)

SBOT.OQ on NASDAQ Stock Exchange Capital Market

0.78USD
22 Feb 2018
Change (% chg)

$-0.02 (-2.42%)
Prev Close
$0.80
Open
$0.80
Day's High
$0.81
Day's Low
$0.78
Volume
4,080
Avg. Vol
14,514
52-wk High
$2.21
52-wk Low
$0.75

Latest Key Developments (Source: Significant Developments)

Stellar Biotechnologies Reports Q1 Loss Per Share $0.13
Wednesday, 7 Feb 2018 04:05pm EST 

Feb 7 (Reuters) - Stellar Biotechnologies Inc ::STELLAR BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.13.‍TOTAL REVENUES FOR QUARTER ENDED DECEMBER 31, 2017 WERE $.02 MILLION COMPARED TO $.14 MILLION FOR SAME PERIOD IN 2016​.  Full Article

Stellar Biotechnologies Q3 loss per share $0.12
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Stellar Biotechnologies Inc :Stellar Biotechnologies reports third quarter 2017 financial results.Q3 loss per share $0.12.Stellar Biotechnologies Inc - total revenues were $0.02 million for quarter ended June 30, 2017 compared to $0.18 million for same period last year.Q3 earnings per share view $-0.11, revenue view $150000.00 -- Thomson Reuters I/B/E/S.  Full Article

STELLAR BIOTECHNOLOGIES Q2 LOSS PER SHARE $0.11
Tuesday, 9 May 2017 04:15pm EDT 

May 9 (Reuters) - Stellar Biotechnologies Inc ::STELLAR BIOTECHNOLOGIES REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.11.STELLAR BIOTECHNOLOGIES INC SAYS TOTAL REVENUES WERE $0.06 MILLION FOR QUARTER ENDED MARCH 31, 2017 COMPARED TO $0.33 MILLION FOR SAME PERIOD LAST YEAR.  Full Article

Stellar Biotechnologies reports FY 2016 financial results
Wednesday, 14 Dec 2016 04:05pm EST 

Stellar Biotechnologies Inc :Stellar Biotechnologies reports fiscal year 2016 financial results.  Full Article

Stellar Biotechnologies Q3 loss per share $0.14
Tuesday, 9 Aug 2016 08:00am EDT 

Stellar Biotechnologies Inc : Q3 loss per share $0.14 .Stellar Biotechnologies reports third quarter 2016 financial results and operational highlights.  Full Article

Stellar Biotechnologies says q3 loss per share $0.14
Tuesday, 9 Aug 2016 08:00am EDT 

Stellar Biotechnologies Inc : Qtrly total revenues of $181,092 compared to $157,748 .says q3 loss per share $0.14.  Full Article

Neovacs and Stellar Biotechnologies launch Neostell, joint venture to manufacture Kinoids
Tuesday, 19 Jul 2016 02:01am EDT 

Neovacs SA : Neovacs and Stellar Biotechnologies announce launch of Neostell, joint venture to manufacture Kinoids .Bernard Fanget, Frank Oakes and Miguel Sieler appointed to administrative board.  Full Article

Frigate Ventures posts 8.3 pct passive stake in Stellar Biotechnologies as of June 30 - SEC Filing
Thursday, 7 Jul 2016 04:24pm EDT 

Stellar Biotechnologies Inc :Frigate Ventures LP reports 8.3 percent passive stake in Stellar Biotechnologies Inc as of June 30 - SEC Filing.  Full Article

Neovacs and Stellar Biotechnologies sign JV agreement to create Neostell
Thursday, 12 May 2016 02:03am EDT 

Neovacs SA : Neovacs and Stellar Biotechnologies sign joint venture agreement to create Neostell . JV owned 70 pct by Neovacs and 30 pct by Stellar Biotechnologies .Beyond interest of 30 pct held by stellar , Neovacs has received 5 million euro for this project from public funding program.  Full Article

Stellar Biotechnologies and Neovacs sign JV
Wednesday, 11 May 2016 10:04am EDT 

Stellar Biotechnologies Inc : Stellar Biotechnologies and Neovacs sign joint venture agreement to manufacture conjugated therapeutic vaccines with Stellar Klh(TM) . Purpose of joint venture is to produce Neovacs' Kinoid immunotherapy product candidates, including Ifna-Kinoid . Joint venture company will be owned initially 70% by Neovacs, with Stellar holding remaining 30% interest . Says under terms of joint venture agreement, Stellar and Neovacs will form a company in France . JV will be governed by 3-member board of directors, two of whom will be appointed by Neovacs and one appointed by Stellar . Says under terms of joint venture agreement, Stellar and Neovacs will form a company in France .Says joint venture has an initial ten-year term, renewable for successive five-year terms.  Full Article

No consensus analysis data available.